- Home
- NAUT vs ALDX Comparison
NAUT vs ALDX Comparison
Compare NAUT & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | ALDX |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4M | 124.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAUT | ALDX |
|---|---|---|
| Price | $0.90 | $1.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $5.50 |
| AVG Volume (30 Days) | 605.6K | ★ 689.5K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.07 | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $992.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $1.07 |
| 52 Week High | $4.31 | $5.93 |
Technical Indicators
Market Signals| Indicator | NAUT | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.50 | 38.51 |
| Support Level | $0.84 | $1.07 |
| Resistance Level | $2.30 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 39.05 | 3.45 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.